December 26, 2004 -- Biotech moved higher last week, without much news, but powered by a backdrop of strong seasonal trends. The January effect, the Santa Claus Rally even the momentum from the past few months all of these forced stocks higher during a quiet, but profitable, week. The Centient Biotech 200 gained just a tad over 1% over the four-day session, rising 37 points to 3573.82. We look at biotech’s gain against other averages, discuss the relative outperformance of big pharma (during the week, not the year), Cambridge Antibody’s rise based on a favorable court ruling, Geron’s new patent, and Adolor’s failed drug trial, which knee-capped its stock.
